Early Evidence of Dose-dependent Pharmacodynamic Activity Following Treatment with SY-5609, a Highly Selective and Potent Oral CDK7 Inhibitor, in Patients with Advanced Solid Tumors

Authors

Kyriakos P. Papadopoulos, South Texas Accelerated Research Therapeutics
Manish R. Sharma, South Texas Accelerated Research Therapeutics
Erika Hamilton, Sarah Cannon Research Institute/Tennessee Oncology
Debra Richardson, Stephenson Cancer Center; Sarah Cannon Research Institute
Babar Bashir, Thomas Jefferson UniversityFollow
Dejan Juric, Massachusetts General Hospital
Geoffrey Shapiro, Dana-Farber Cancer Institute
Graeme Hodgson, Syros Pharmaceuticals
Nan Ke, Syros Pharmaceuticals
Anthony D'Ippolito, Syros Pharmaceuticals
Liv Johannessen, Syros Pharmaceuticals
Qing Kang-Fortner, Syros Pharmaceuticals
Li Zhou, Syros Pharmaceuticals
Maria Rosario, Syros Pharmaceuticals
William Zamboni, Syros Pharmaceuticals
Hina A. Jolin, Syros Pharmaceuticals
Catherine Madigan, Syros Pharmaceuticals
Michael J. Kelly, Syros Pharmaceuticals
David A. Roth, Syros Pharmaceuticals

Files

Publication Date

10-2020

Disciplines

Medicine and Health Sciences | Oncology

Comments

Presented at the 2020 ENA Virtual Symposium

Recommended Citation

Papadopoulos, Kyriakos P.; Sharma, Manish R.; Hamilton, Erika; Richardson, Debra; Bashir, Babar; Juric, Dejan; Shapiro, Geoffrey; Hodgson, Graeme; Ke, Nan; D'Ippolito, Anthony; Johannessen, Liv; Kang-Fortner, Qing; Zhou, Li; Rosario, Maria; Zamboni, William; Jolin, Hina A.; Madigan, Catherine; Kelly, Michael J.; and Roth, David A., "Early Evidence of Dose-dependent Pharmacodynamic Activity Following Treatment with SY-5609, a Highly Selective and Potent Oral CDK7 Inhibitor, in Patients with Advanced Solid Tumors" (2020). Department of Medical Oncology Posters. 12.
https://jdc.jefferson.edu/medoncposters/12